The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo

@article{Wickstrm2007TheNM,
  title={The novel melphalan prodrug J1 inhibits neuroblastoma growth in vitro and in vivo},
  author={Malin Wickstr{\"o}m and John Inge Johnsen and Frida Ponthan and Lova Segerström and Baldur Sveinbjörnsson and Magnus Lindskog and Henrik L{\"o}vborg and Kristina Viktorsson and Rolf Lewensohn and Per Kogner and Rolf Larsson and Joachim Gullbo},
  journal={Molecular Cancer Therapeutics},
  year={2007},
  volume={6},
  pages={2409 - 2417}
}
Neuroblastoma is the most common extracranial solid tumor of childhood. The activity of J1 (l-melphalanyl-p-l-fluorophenylalanine ethyl ester), an enzymatically activated melphalan prodrug, was evaluated in neuroblastoma models in vitro and in vivo. Seven neuroblastoma cell lines with various levels of drug resistance were screened for cytotoxicity of J1 alone or in combination with standard cytotoxic drugs, using a fluorometric cytotoxicity assay. J1 displayed high cytotoxic activity in vitro… Expand
In vitro and in vivo activity of melflufen (J1)in lymphoma
TLDR
This study confirms previous reports of a targeting related potency superiority of melflufen compared to that of melphalan and appears to be a candidate for further evaluation in the treatment of this group of malignant diseases. Expand
The novel alkylating prodrug melflufen (J1) inhibits angiogenesis in vitro and in vivo.
TLDR
This study demonstrates through all methods used, that melphalan-flufenamide besides being an alkylating agent also reveals anti-angiogenic effects in different preclinical models in vitro and in vivo. Expand
In vitro and in vivo activity of melflufen ( J 1 ) in lymphoma
Background: Melphalan has been used in the treatment of various hematologic malignancies for almost 60 years. Today it is part of standard therapy for multiple myeloma and also as part ofExpand
In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells
TLDR
The preclinical study supports clinical evaluation of mel-flufen to enhance therapeutic potential of melphalan, overcome drug-resistance, and improve multiple myeloma patient outcome. Expand
The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro
TLDR
The ex vivo profile of J 1 suggests that further evaluation of J1 as the alkylating agent in for example aggressive breast cancer might be of particular interest, preferentially in combination with DNA-topoisomerase II inhibitors like etoposide. Expand
In vitro and in vivo anti-leukemic activity of the peptidase-potentiated alkylator melflufen in acute myeloid leukemia
TLDR
Melflufen demonstrates high and significant preclinical activity in AML and further clinical evaluation seem warranted in this disease, as well as in a patient derived xenograft study. Expand
Cancer Therapy : Preclinical In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent , Melphalan-Flufenamide , against Multiple Myeloma Cells
TLDR
The preclinical study supports clinical evaluation of mel-flufen to enhance therapeutic potential of melphalan, overcome drug-resistance, and improve multiple myeloma patient outcome. Expand
Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide
TLDR
Melflufen has shown an anti-proliferative effect in HGOS ex vivo samples and cell lines, including those resistant to methotrexate, etoposide, doxorubicin, and PARP inhibitors, and this sensitivity correlated with high expression of ANPEP. Expand
The novel pyrrolo-1,5-benzoxazepine, PBOX-6, synergistically enhances the apoptotic effects of carboplatin in drug sensitive and multidrug resistant neuroblastoma cells.
TLDR
The ability of two members of the pyrrolo-1,5-benzoxazepine group, PBOX-6 and -15, to exhibit anti-cancer effects in a panel of drug sensitive and MDR neuroblastoma cell lines is examined, indicating the potential of the PBOX compounds in enhancing chemosensitivity in neuroblastomas. Expand
The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan.
TLDR
A role of APN in the activation of the melphalan prodrug J1 and subsequently, its cytotoxic effects is demonstrated and data suggest that J1 may be activated in a tumor selective manner. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 32 REFERENCES
Celecoxib Prevents Neuroblastoma Tumor Development and Potentiates the Effect of Chemotherapeutic Drugs In vitro and In vivo
TLDR
Celecoxib potentiates the antitumor effect of chemotherapeutic drugs currently used in neuroblastoma treatment, which argues for clinical trials combining these drugs. Expand
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo
TLDR
The results indicate that the promising in vitro data from the previous studies of J1 seems translatable into the in vivo situation, and at equal doses of alkylating units J1 was more active in the mouse hollow-fiber model, but showed similar general toxicity. Expand
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
TLDR
TPT cytotoxicity appears to be enhanced more by combination with certain DNA-damaging agents than by combination in combination with antimetabolites or antimicrotubule agents. Expand
Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing Prodrug J1
TLDR
The results show that the activity of the dipeptide mustards is highly dependent on intracellular hydrolysis, which result in rapid intrACEllular release of the alkylating unit in cells with high enzymatic activity. Expand
Antitumor activity of the alkylating oligopeptides J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester) and P2 (L-prolyl-m-L-sarcolysyl-p-L-fluorophenylalanine ethyl ester): comparison with melphalan
TLDR
In the present study the in vitro activity of P2 was further investigated and compared to melphalan and the novel alkylating dipeptide J1 (L-melphalanyl-p-L-fluorophenylalanine ethyl ester), which is structurally related to P2 andmelphalan. Expand
Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
TLDR
It is shown that SIL loaded with doxorubicin (DXR) and targeted to the disialoganglioside receptor GD(2) [aGD(2)-SIL(DXR)] led to a selective inhibition of the metastatic growth of experimental models of human neuroblastoma. Expand
Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives.
TLDR
The results indicate that the activity of these compounds not only relies on their chemical reactivity, but also on active biological interactions such as transport across membranes and/or enzymatic liberation of reactive molecular entities. Expand
Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma.
TLDR
Treatment with (131)I-MIBG in combination with myeloablative chemotherapy and hematopoietic stem-cell rescue is feasible with acceptable toxicity and future study is warranted to examine the efficacy of this novel therapy. Expand
The synthetic retinoid RO 13‐6307 induces neuroblastoma differentiation in vitro and inhibits neuroblastoma tumour growth in vivo
TLDR
Preclinical results suggest that Ro 13‐6307 may be a candidate retinoid for clinical oral therapy of neuroblastoma in children, where the effect seems to depend on dose, scheduling and tumour mass. Expand
Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice
TLDR
The pharmacokinetic profile for CPT-11 and its metabolites in the esterase-deficient mice more closely reflects that seen in humans, suggesting these mice may represent a more accurate model for antitumor studies with this drug and other agents metabolized by CEs. Expand
...
1
2
3
4
...